- Dominion (D) to buy from hold at Deutsche Bank.
- Corinthian Colleges (COCO) to outperform from underperform at RBC Capital.
- Canadian National (CNI) to sector outperformer from sector performer at CIBC.
- DragonWave (DRWI) to buy from hold at Jefferies.
- Infosys (INFY) to overweight from equal weight at Morgan Stanley.
- SL Green Realty (SLG), Lexington Realty (LXP) and Taubman Centers (TCO) to overweight from neutral at JPMorgan.
- Sunstone Hotel (SHO) to buy from neutral and Extra Space Storage (EXR) to buy from hold at KeyBanc.
DRWI posts
FeedAnalyst Calls: AEP, CCL, CNI, D, FDX, HAS, INFY, MAT, RCL, S, T, UPS, VZ ...
Continue reading Analyst Calls: AEP, CCL, CNI, D, FDX, HAS, INFY, MAT, RCL, S, T, UPS, VZ ...
Analyst Calls: WDC, Q, HSY, BWLD, NOK, COP, KFT, VZ ...
- Deutsche Bank upgraded Sonoco Products (SON) to buy from hold after the company reported Q1 results and raised guidance. The firm upped its target for shares to $38 from $32.
- Baird upgraded Western Digital (WDC) to outperform from neutral following the solid Q3 report and guidance. The firm raised its target to $50 from $48.
- Goldman upgraded Qwest (Q) to neutral from sell. Qwest is being acquired by CenturyLink (CTL).
- Hershey (HSY) was upgraded to neutral from underweight at JPMorgan.
- Principal Financial (PFG) was upgraded to neutral from sell at UBS.
- Monster Worldwide (MWW) was upgraded to market perform from underperform at Wells Fargo.
Continue reading Analyst Calls: WDC, Q, HSY, BWLD, NOK, COP, KFT, VZ ...
Analyst upgrades, downgrades and initiations: CVS, FICO, HOTT, INTC, MNTA, TXN ...
- Oppenheimer upgraded Momenta Pharmaceuticals (MNTA) to outperform from perform as it finds the stock attractive ahead of FDA's decision on M-enoxaparin. The firm has a $15 price target on the stock.
- Wells Fargo upgraded Symmetry Medical (SMA) to market perform from underperform. The firm cited several factors for the upgrade, including valuation and its belief that Symmetry's customers have begun to deplete their inventories.
- Piper Jaffray upgraded Myriad Pharmaceuticals (MYRX) to neutral from underweight after the company announced Phase 2a date for Azixa. The firm has a $5 price target on shares.
- AvalonBay (AVB) and Mid-America Apartment (MAA) were upgraded to outperform from sector perform at RBC Capital.
- GSI Commerce (GSIC) was upgraded to overweight from equal weight at Morgan Stanley.
- FICO (FICO) was upgraded to equal weight from Underweight at Stephens.
Continue reading Analyst upgrades, downgrades and initiations: CVS, FICO, HOTT, INTC, MNTA, TXN ...
5-Hour Energy: A Success Equal Parts Caffeine, Chemistry and…
Suddenly, Amazon Doesn't Love Its Moms Anymore
.gif)



